Latest News and Press Releases

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial, Securing Alignment with FDA and EMA

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)